Synta reports positive ganetespib results
January 2014

LEXINGTON, Mass.—Synta Pharmaceuticals Corp. has announced a pair of published preclinical studies recently supporting the activity of ganetespib, a potent, selective inhibitor of the Hsp90 chaperone protein, as well as recent results from a clinical treatment setting of triple-negative breast cancer—the drug is being studied in more than 25 clinical trials overall. The publications demonstrate that the compound is capable of down-regulating several key proteins related to tumor growth and metastasis, including HIF- 1alpha, which is a key regulator of multiple tumor growth properties such as angiogenesis, metastasis, metabolism, cancer stem cell maintenance and invasion. In addition, the publications showed that inhibiting several protein targets, including HIF-1alpha, correlates with potent effects on the viability and metastasis of triple-negative breast cancer tumor cells when ganetespib is administered alone or in combination with other chemotherapeutics.

Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.